Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 5:58 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 13,062 matching trials from the live ClinicalTrials.gov search.

Filters: Atlanta, Georgia Clear all

Conditions: Esophageal and Gastric Varices, Liver Cirrhosis
Interventions: Transjugular Intrahepatic Portosystemic Shunt (TIPS), Distal Splenorenal Shunt; Procedure
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2003
U.S. locations: 5
States / cities: Miami, Florida • Atlanta, Georgia • Cleveland, Ohio + 2 more

Conditions: Diabetes Mellitus, Non-Insulin-Dependent
Interventions: Glucovance (metformin HCl/glyburide), metformin HCl, glyburide; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 9 Years to 16 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 50
States / cities: Birmingham, Alabama • Tucson, Arizona • Beverly Hills, California + 43 more

Conditions: Smoking, Tobacco Use, Tobacco Smoking
Interventions: 40007388, 40007385, 40007387, 40007386; Other
Lead sponsor: RAI Services Company; Industry
Eligibility: 21 Years to 60 Years
Enrollment: 1,180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 10
States / cities: Atlanta, Georgia • Chicago, Illinois • Baltimore, Maryland + 7 more

Conditions: Advanced Multiple Myeloma
Interventions: Filanesib, KSP (Eg5) inhibitor; intravenous, Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 29
States / cities: Birmingham, Alabama • Duarte, California • San Francisco, California + 24 more

Conditions: Sexually Transmitted Infection
Interventions: Doxycycline; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 59 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Narcolepsy
Interventions: SEP363856, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 6
States / cities: Orange, California • St. Petersburg, Florida • Atlanta, Georgia + 3 more

Conditions: Osteosarcoma, Pulmonary Recurrence of Osteosarcoma
Interventions: Surgical Resection, Stereotactic Body Radiation Therapy (SBRT), Atezolizumab; Procedure · Radiation · Drug
Lead sponsor: Emory University; Other
Eligibility: Up to 50 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Dyslipidemia
Interventions: Pitavastatin, Pravastatin; Drug
Lead sponsor: Kowa Research Institute, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 35
States / cities: Phoenix, Arizona • Beverly Hills, California • Costa Mesa, California + 32 more

Conditions: Kidney Transplant Rejection
Interventions: Frexalimab, Tacrolimus, rabbit anti-thymocyte globulin, mycophenolate mofetil, mycophenolate sodium, methylprednisolone, prednisone; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 526 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 14
States / cities: San Francisco, California • Atlanta, Georgia • Hines, Illinois + 9 more

Conditions: Lupus Nephritis
Interventions: VIB4920, Placebo for VIB4920; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 17
States / cities: La Jolla, California • Los Angeles, California • Orange, California + 13 more

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: natalizumab, interferon beta 1-a, methylprednisolone, IV placebo, glatiramer acetate; Drug · Other
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 20
States / cities: Cullman, Alabama • San Francisco, California • Fort Collins, Colorado + 15 more

Conditions: Colorectal Cancer, Metastatic Cancer
Interventions: Postoperative chemotherapy, Perioperative chemotherapy; Procedure
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 283
States / cities: Antioch, California • Duarte, California • Fremont, California + 210 more

Conditions: Symptomatic Severe Aortic Stenosis
Interventions: TAVR Implantation of the THV Prosthesis; Device
Lead sponsor: Edwards Lifesciences; Industry
Eligibility: 19 Years and older
Enrollment: 583 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 39
States / cities: Los Angeles, California • Sacramento, California • Stanford, California + 34 more

Conditions: Atrial Fibrillation
Interventions: RSD1235; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 10
States / cities: Huntsville, Alabama • Atlanta, Georgia • Chicago, Illinois + 7 more

Conditions: Bipolar I Disorder
Interventions: Intramuscular (IM) Depot Aripiprazole, Intramuscular (IM) Depot Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 731 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 42
States / cities: Birmingham, Alabama • Springdale, Arkansas • Beverly Hills, California + 39 more

Conditions: Benign Prostatic Hyperplasia
Interventions: GreenLight XPS Laser System; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: Male only
Enrollment: 956 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 5
States / cities: Mountain View, California • Atlanta, Georgia • Westland, Michigan + 2 more

Conditions: Stroke, Sleep Wake Disorders, Rehabilitation, Recovery of Function
Interventions: Observation; Other
Lead sponsor: State University of New York - Upstate Medical University; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Timeline: 2021 – 2025
U.S. locations: 6
States / cities: Atlanta, Georgia • Kansas City, Kansas • Syracuse, New York + 1 more

Conditions: Bacterial Vaginosis
Interventions: SYM-1219; Drug
Lead sponsor: Symbiomix Therapeutics; Industry
Eligibility: 12 Years and older · Female only
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 40
States / cities: Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 34 more

Conditions: Cardiovascular Diseases
Interventions: PATH Intervention, Attention Control Intervention, Physical activity tracker, Dietary education; Behavioral · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Refractory Major Depressive Disorder
Interventions: ALKS 5461; Drug
Lead sponsor: Alkermes, Inc.; Industry
Eligibility: 18 Years to 72 Years
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 29
States / cities: Tucson, Arizona • Little Rock, Arkansas • Los Alamitos, California + 26 more

Conditions: Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Ambiguous Lineage Leukemia or Lymphoma, Myeloma
Interventions: FLT; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 4 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Atlanta, Georgia • Oklahoma City, Oklahoma

Conditions: Primary Pulmonary Hypertension
Interventions: LIQ861 Inhaled Treprostinil; Drug
Lead sponsor: Liquidia Technologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 38
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 30 more

Conditions: Non Small Cell Lung Cancer
Interventions: RAD001, erlotinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 7
States / cities: Atlanta, Georgia • Chicago, Illinois • Boston, Massachusetts + 4 more

Conditions: Closed Fracture, Open Fracture
Interventions: Grafton DBM, Reamings; Device · Biological
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Atlanta, Georgia

Search by objective public record fields.

Decompression Intervention of Variceal Rebleeding Trial (DIVERT)

A Research Study to Determine the Safety and Efficacy of Glucovance Compared to Metformin and Glyburide in Children and Adolescents With Type 2 Diabetes.

CSD210904: Study to Assess Actual Use of a Heated Tobacco Product With Four Non-Combusted Cigarette Variants in Current Adult Smokers

A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)

Daily Doxycycline to Inform Sexually Transmitted Infection Prophylaxis Regimens

This is a Study to Determine the Effect of Multiple Doses of an Investigational Drug, Taken by Mouth, in People With Narcolepsy-cataplexy. Accepting Both Males and Females Ages of 18 Years to 55 Years. This Study Will be Conducted in the US and Will Require Approximately 13 Weeks Participation.

Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma

A 12-Week Study Comparing Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV-Infected Subjects

A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation

VIBRANT: VIB4920 for Active Lupus Nephritis

Treatment Interruption of Natalizumab

Combination Chemotherapy Before or After Surgery in Treating Patients With Colorectal Cancer With Liver Metastases That Could Be Removed By Surgery

PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - High Risk and Nested Registry 7

Study of RSD1235 to Evaluate Safety in Patients With Atrial Fibrillation

Efficacy, Safety, and Tolerability of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Bipolar I Patients

GreenLight XPS Laser System Retrospective Chart Review

The SLEEPR Study: SLEep Effects on Post-stroke Rehabilitation

Open-Label Study to Evaluate Safety of A Single Dose of SYM-1219

Web-based Physical Activity Intervention to Promote Physical Activity

A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive Disorder (MDD)

Pilot Imaging Study of Leukemia

Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil

Combination of RAD001 and Erlotinib in Patients With Advanced Non Small Cell Lung Cancer Previously Treated Only With Chemotherapy

Efficacy of DBM on Fractures of the Shinbone (Tibia)